AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence